Sign inJoin waitlistJoin the waitlist

FH

Frank Haluska

Physician · New York Presbyterian Hospital

Credentials: · · ·

History

New York Presbyterian Hospital
Present

Medical Oncology
Internal Medicine

Research

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
New England Journal of Medicine · 2004 · 9,364 citations
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
New England Journal of Medicine · 2013 · 890 citations
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Proceedings of the National Academy of Sciences of the United States of America · 2003 · 788 citations

AS
Arthur Sober
12 papers
Hensin Tsao
11 papers · 3 as a fellow
Stephen Hodi
10 papers · 1 as a fellow
Victor Rivera
9 papers
Jorge Cortes
8 papers
MT
Moshe Talpaz
8 papers
Gerald Linette
7 papers · 5 as a fellow
Hagop Kantarjian
7 papers
MM
Martin Mihm
7 papers
Michael Deininger
7 papers
Neil Shah
7 papers
Kenneth Tanabe
6 papers

Grants

Genetics of RAS, PTEN, BRAF and CDKN2A in Melanoma
National Cancer Institute · R01
Contact PI · $584.5K · Tufts Medical Center
2005–2010
Peptide-Pulsed Dendritic Cell Therapy for Melanoma
National Cancer Institute · R03
Contact PI · $171K · Massachusetts General Hospital
1999–2002

Clinical trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Principal investigator · Unknown · Phase 2
Dana-Farber Cancer Institute
2004
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Study chair · Completed · Phase 3
SWOG Cancer Research Network
2000–2012
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
Study director · Completed · Phase 2
Merck Sharp & Dohme LLC
2005–2007